Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions

Namarta Kalia¹, Jatinder Singh¹* and Manpreet Kaur²*

¹ Department of Molecular Biology and Biochemistry, Guru Nanak Dev University, Amritsar, India, ² Department of Human Genetics, Guru Nanak Dev University, Amritsar, India

Recurrent vulvovaginal infections (RVVI), a devastating group of mucosal infection, are severely affecting women’s quality of life. Our understanding of the vaginal defense mechanisms have broadened recently with studies uncovering the inflammatory nature of bacterial vaginosis, inflammatory responses against novel virulence factors, innate Type 17 cells/IL-17 axis, neutrophils mediated killing of pathogens by a novel mechanism, and oxidative stress during vaginal infections. However, the pathogens have fine mechanisms to subvert or manipulate the host immune responses, hijack them and use them for their own advantage. The odds of hijacking increases, due to impaired immune responses, the net magnitude of which is the result of numerous genetic variations, present in multiple host genes, detailed in this review. Thus, by underlining the role of the host immune responses in disease etiology, modern research has clarified a major hypothesis shift in the pathophilsophy of RVVI. This knowledge can further be used to develop efficient immune-based diagnosis and treatment strategies for this enigmatic disease conditions. As for instance, plasma-derived MBL replacement, adoptive T-cell, and antibody-based therapies have been reported to be safe and efficacious in infectious diseases. Therefore, these emerging immune-therapies could possibly be the future therapeutic options for RVVI.

Keywords: adaptive immunity, innate immunity, oxidative stress, evasion, single nucleotide polymorphisms (SNPs), pattern recognition receptors (PRRs), infectious diseases

INTRODUCTION

Vulvovaginal infections (VVI) are the commonly reported microbiological syndrome affecting millions of women globally in all strata of society. An abnormal vaginal discharge is the key trait and first sign of VVI that women seeking health care frequently complaint to gynecologist. About a quarter of all adult women complain about abnormal vaginal discharge, more commonly by those belonging to Indian subcontinent i.e., South Asia (1). Moreover, the repeated experiences of common vaginal infections collectively known as recurrent VVI (RVVI) are emerging and are the major concern for researcher these days. The three common RVVI are Bacterial Vaginosis (BV), Vulvovaginal Candidiasis (VVC), and Trichomoniasis (TV) (2). The recurrence rate of BV (RBV) is as high as 30–50% within 3 months while ≥ 4 repetitive episodes of VVC in 12-months are referred as recurrent VVC (RVVC) (3). Similarly, cases of recurring TV (RTV) have also been reported with recurrence rates as high as 5–8% within 2 months of initial diagnosis (4). The milieu conditions of vagina during one VVI type create a niche for the pathogenesis of other VVI, leading to Mixed...
Infections (MI) and co-infections (5, 6). These VVI, left untreated, will not only affect the female reproductive health, but may also result in many foster infections/diseases and adverse pregnancy outcomes (7–9).

The literature regarding RVVI pathogenesis has suggested that “a vaginal microbiota (VMB) dominated with Lactobacilli is healthier than a diverse VMB.” This diversity in VMB causes dysbiosis characterized by fall in number of Lactobacilli and overgrowth of opportunistic pathogens that are either normally present in human VMB in lower quantity or sexually transmitted, resulting in RVVI (10). However, the decades of research failed to find a single pathogen responsible for causing common RVVI. This is because 20–30% of healthy (asymptomatic) women were found to have VMB same as that of VVI women (11). Also, some Lactobacilli strains, i.e., L. iners and L. jensenii, were found to be pathogenic and associated with VMB instability in pregnant women, pre-term birth, and BV (12,13). Therefore, the present scenario doesn’t satisfy the Koch's postulates, according to which the causative agent is essential for causing disease and it should not be present in population without disease (14). Due to this reason, accurate definition of vaginal health and vaginal infections is still lacking till date. Besides this, there are other local risk factors that have also been suggested to create favorable conditions for the development of RVVI (15). However, development of RVVI in women lacking any of these recognized disposing factors, suggests the involvement of host immune components, instrumental in elimination of RVVI pathogens (16). Further suggesting that, it’s the host immune system that determines the disease outcome and thus must be explored to get an accurate definition of vaginal health and infections.

Thus, an attempt has been made, to achieve a clear understanding of host immunity in three common RVVI. This review commences with a brief summary of what is known about immunology of human vagina. Different studies that contributed to host defenses against common RVVI were then addressed and linked. These protective immune mechanisms lead to oxidative stress that has been shown to play a major role in pathophysiology of common RVVI. The review further fine points the hijacking or exploitation of host immune responses by RVVI pathogens. A theory and related mechanism was then proposed to explain the immunopathogenesis of RVVI. Moreover, genetic variations in immune molecules have been shown to play an important role in how a woman responds to a particular RVVI challenge, as evidenced by several genetic disease association studies that are detailed in this review. Based on this comprehensive compilation, different strategies were proposed for treatment of RVVI that may prevent recurrence of these enigmatic infections.

**IMMUNOLOGY OF HUMAN VAGINA**

The human vagina consists of multiple levels of protection in form of innate and adaptive immunity that is further compartmentalize into various components and is under strong hormonal control. Inflammation signifies an essential immune mechanism that is meant to eliminate pathogens and repair damage caused by deleterious stimuli. Theoretically, inflammation is a process that involves four stages, including an activating system, a sensing mechanism, signal diffusion, and the effector cells activation (17). In infectious diseases, the activating system is pathogen that has preserved biomolecular structures on its surface known as pathogen associated molecular patterns (PAMPs). These PAMPs lead to the activation of quick and non-specific innate immunity that further signals for the activation of specific adaptive immunity, with the ultimate goal of eradicating the pathogens and repairing tissue damage elicited by the noxious stimuli (17).

### Innate Immunity in Human Vagina

The innate immunity of human vagina involve physical, chemical, and cellular components (18). Interactions between these components form a complex microenvironment that mediates immune responses in vagina, regulated by sex hormones and specific microbiome (19).

#### Physical Barriers

Mucosal lining and epithelial cells serve as gatekeepers preventing the entry of pathogens in to vagina (20). The gel like mucosal layer is produced by the mucin proteins expressed by the surface of upper layer of epithelial cells throughout the vagina (21). Besides entrapping the invasive pathogens, the vaginal mucosal layer also provides lubrication and acts as a source of nutrition for the VMB. In turn, the VMB of healthy women (dominated by Lactobacilli) contributes to the physical defense of vaginal mucosa against pathogens by maintaining low pH, producing lactic acid, and other antimicrobial substances (22). Thus, VMB is capable of modulating defense property of vaginal mucosa. However, many physiological processes including menstruation, conception, pregnancy, and the hormonal changes frequently modulate the vaginal mucosal immune system (23). The stratified squamous vaginal epithelium, underlying the mucosal layer, also as acts as a barrier and first responder to pathogens by “sensing” the danger leading to immune cell activation and secretion of immune mediators driving inflammation and immune responses (24). The identified danger is the damage done to vaginal epithelial cells by virulence factors secreted by the pathogens. These damaged host cells derived immune mediators are called damage-associated molecular patterns (DAMPs, danger signals, or alarmins) that constitute the parts of chemical components of immune system. Beneath the epithelium is lamina propria that is composed primarily of fibroblasts, blood vessels, and a diversity of immune cells (explained under cellular components).

#### Chemical Components

DAMPs, PRRs, chemotactic cytokines, AMPs, and C system make the chemical components of innate immune system of vagina. Other than injured host cells, DAMPs are also released under conditions like necrosis, apoptosis, and by collapsed extracellular matrix (25). Some examples of intracellular DAMPs includes DNA, fibronectin, high mobility group box-1 (HMGB1), S-100 proteins, heat shock proteins, hyaluronic acid, formyl peptides, ATP, and collagen or elastin derived peptides (25). In order to discriminate own cells from pathogens, the vaginal
immune system employ pattern recognition receptors (PRRs), that specifically respond to various pathogens (26). Currently, PRRs are divided into five major families including Toll-like receptors (TLRs), C-type lectin receptors (CLRs), the nucleotide-binding oligomerization domain (NOD) like receptors (NLRs), retinoic acid-inducible gene (RIG) I-like receptors (RLRs), and absent in melanoma 2 (AIM2)-like receptors (ALRs) (27). The PRRs expressed by squamous vaginal epithelial cells include TLRs i.e., TLR1–10 except TLR7, CLRs including dendritic cell-associated c-type lectin-1 (Dectin-1) and secretary mannose binding lectin (MBL) as well as NOD receptor including NOD1 (18, 28–32). The expression of TLR4 and Dectin-1 in the vaginal epithelial cells is controversial as some studies have shown their presence, while others reported their absence (28, 33, 34). Also, the MBL levels in vaginal fluid are partly contributed from plasma, as a result of transudation, though directly secreted by local vaginal epithelial cells (32). However, almost all the known human TLRs, CLRs and intracellular PRRs are expressed by immune cells of both myeloid (neutrophils, macrophages and dendritic cells) and lymphoid origin (B and T cells) present in lamina propria or in vagina due to transmigration (29, 30). Upon stimulation, either through direct contact of PAMPs or through indirect means (DAMPs or cytokines), these PRRs initiates a signaling cascade, that includes activation of transcription factors, release of antimicrobial peptides (AMPs) as well as chemotactic cytokines that further signals for the activation of adaptive immunity and subsequent amplification of innate immune responses, leading to the ultimate killing of pathogens (35).

AMPs are generally expressed by numerous cell types of vagina primarily by neutrophils and epithelial cells, with small fractions contributed by dendritic cells (DCs), macrophages, and natural killer (NK) cells (36). These AMPs have antimicrobial properties against bacteria, fungus, parasite, and virus (23, 36). Different AMPs that have been reported in lower genital tract include defensins, protease inhibitors, including serine protease inhibitors (serpins), secretory leukocyte protease inhibitor (SLPI), human epididymis protein 4 (HE4), cystatins, elafins, lysozyme, lactoferrin, and cathelicidin (LL-37). Out of these, human defensins [both alpha (α) and beta (β)] are among the most widely characterized and abundant AMPs present in lower genital tract including vagina (18, 23, 37). Besides antimicrobial properties, these AMPs can destroy target cells through modulating pH and ionic concentration gradient and also have been shown to have chemotactic activity (36). The detailed mechanisms of action for each AMP have been comprehensively reviewed elsewhere (36, 38, 39). As mentioned, all the immune and vaginal epithelial cells upon activation release chemical messengers called cytokines that create an aggressive milieu for the pathogen either by creating a network between the different immune cell types or by providing direct antimicrobial response (20). Different cytokines are released based on different stimuli and cell type. Other than this, the complement (C) system, a humoral component of the innate immune system, is actively involved in the host protection against vaginal infections (40). The C system recognizes the pathogens by utilizing three different molecules i.e., C1q, MBL (also a CLR) and C3, that respectively trigger the classical, lectin and alternative pathways for pathogen elimination (41).

**Cellular Components**

Inflammatory immune cells e.g., Neutrophils, Macrophages, NK cells, and DCs, which are either resident (like epithelial cells) or transmigrated into the genital tract in response to DAMPs or chemotactic cytokines, form the cellular components of innate immune system (42). Neutrophils are the major cells that are recruited at the site of infection, mediating an inflammatory response against pathogens. Neutrophils are present throughout the female reproductive tract with pre-dominant number in fallopian tubes. However, the quantity steadily reduced from the upper genital tract to vagina (23, 42). However, upon infection, under the influence of chemotactic cytokines e.g., IL-8, abundant amounts of neutrophils penetrate from vaginal epithelium into the lumen to phagocytise the pathogens and cellular debris (43). Furthermore, the proportion of these neutrophils also increases prior to menses, due to the natural process of tissue breakdown, and during copulation for the phagocytosis of sperm (18). Other than phagocytosis, these neutrophils also respond to pathogens through production of oxidative compounds, leading to oxidative stress, by releasing AMPs and cytokines for its own stimulation or for the recruitment of other cells. Other important innate immune phagocytic cells include macrophages, DCs and NK cells that constitute 10% of the total leukocytes present in the female genital tract (18, 44). Macrophages and DCs act as professional antigen presenting cells (APCs) for inducing of adaptive immune responses (45). Moreover, only DCs in particular act as a main mediator for bridging the innate and adaptive immunity and generate life-long memory by priming naïve T-cells (46). In addition, NK cells in vagina lead to macrophage activation and generate pro-inflammatory and cytotoxic T cell responses (18, 20).

**Adaptive Immunity of Human Vagina**

The adaptive immune system of female reproductive tract presents distinctive characteristics that are unique from the adaptive immunity of other mucosal surfaces (18). It involves immunoglobulins and various cellular components (18, 47).

**Chemical Components**

Different studies have documented antibody (the humoral component of adaptive immunity) responses against vaginal infections based on *in vivo* or *in vitro* experiments and suggested weak but consistent presence of IgG and IgA antibodies in vaginal secretions (47). Although both antibodies are present in genital secretions, IgG was found to be more predominant than IgA (48). These antibodies prevent colonization of pathogen by checking their adherence to vaginal epithelial cells and contribute to the neutralization and formation of Ag-Ab complexes, helping in uptake and clearance of pathogen by phagocytic cells of vagina (47, 48).

**Cellular Components**

The cellular components of vaginal adaptive immunity include effector B-cell, CD4⁺, and CD8⁺ T cells responses as well as
local B and T memory cells that are found throughout the female reproductive tract. The T cells in vaginal tissue are localized at the stroma/epithelial interface and are few in number (49, 50). Moreover, recent studies have also suggested the presence of T-helper 17 (Th17) cells and regulatory T (Treg) cells in vagina (51). Other than this, various immuno-histochemical studies have shown the presence of antibody-producing B cells with low prevalence in vagina, ectocervix, and fallopian tubes relative to endocervix (47). However, during inflammation the number of intra-epithelial lymphocyte population increases relative to non-inflamed vagina.

**IMMUNOLOGICAL HOST DEFENSES AGAINST COMMON RVVI**

To maintain homeostasis and minimize the risk of infection, host vagina is capable and competitive enough to generate different immune responses against different vaginal infections as given in detail below:

**Immunity in BV**

Studies based on transcriptional profiling and markers assessment in vaginal secretions and serum has indicated the major involvement of host immunity in BV (Figure 1). Assessment of vaginal secretions in BV women has shown the stimulation of nuclear factor-xB (NF-xB) in various cell types, which is the characteristic factor involved in proinflammatory signaling pathways of many TLRs (52). However, the major TLR found to be involved in BV pathology is TLR4, whose expression in monocytes is shown to be strikingly increased on exposure to lavage samples of BV women (53). Moreover, it was shown that sensing of BV associated bacteria is facilitated *in situ* via TLR4 signaling, through NF-xB pathway leading to lymphocytes enrolment by cytokines secretion, thus causing genital inflammation (54). Other than this, immunofluorescence analysis of clue cells from BV patients revealed the presence of MBL and C3 on clue cells suggesting their direct role in recognition of BV associated bacteria (BVAB) and activation of both lectin and alternative pathways of complement system (40). Complementary evidence recommended that the chances of acquiring BV will be more in cases with insufficient sMBL levels (55). Expression of Dectin-1, another PRR, was found to increase upon stimulation with bacterial LPS relative to primarily observed low expression in freshly isolated human peripheral blood monocytes (PBMCs) and human monocytes cell line detected by both qPCR for mRNA and FACS staining for cell surface protein expression (56). In consonance, high serum Dectin-1 levels were observed in BV patients relative to controls, suggesting the active role played by Dectin-1 in defense against BV (57).

In addition, cytokines have been shown to directly contribute to BV pathology, as, BV was found to induce milieu enriched with proinflammatory cytokines in the lower genital tract. These include IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-1B, IL-10, TNF-α, IFN-γ, FMS-like tyrosine kinase 3 ligand, chemokine C-C motif ligand 5 (CCL5), and SLPI [compiled in 58 and currently reported in Jespers et al. (58) and Lennard et al. (59)]. These studies supported the concept that BV triggers the innate immune responses, which was also assessed independently for individual bacterial species present in VMB of BV patients. For example, *A. vaginae* was found to induce expression of IL-1B, IL-6, IL-8, CCL20, human β defensin-2 (HBD-2), and TNF-α via NF-xB, TLR2, and MyD88 signaling pathways; *G. vaginalis* was found to induces IL-1B, IL-18, IL-6, IL-8, and TNF-α; *Mobiluncus curtisi* and *Prevotella bivia* induced IL6, IL8, G-CSF, IP-10, MIP-1B, RANTES, and Gro-a (60–64).

Of all the associated pro-inflammatory cytokines, IL-1β was consistently been linked with BV, with four to over 10-fold higher levels than controls, validated both by earlier as well as current studies (58, 65–75). Moreover, successful treatment of BV has been shown to normalize the elevated pro-inflammatory cytokines levels (76). IL-1β, a pro-inflammatory cytokine produced by innate immune cells, is a key mediator of the inflammatory response and is essential for the host-defense and resistance to pathogens (77). IL-1β has a special role in the altering production of pro-inflammatory cytokines such as IL-8, IL-6, and TNF-α and found to be positively correlated with their levels and cell surface expression of TLR4 in human epithelial cells (78). This suggests that the secondary pro-inflammatory cytokines should also increase with increase in IL-1β levels during BV. This was further confirmed by studies that have found higher levels of IL-8 in women with BV (67, 72). In contrast, inconsistent but elevated expression of IL-1α was also found to be associated with BV (65, 79, 80).

Other than cytokines, AMPs, particularly defensins, were found to be associated with BV, though their role in pathogenesis is not clear due to inconsistencies in the results obtained. Elevated expression of human α-defensins, mainly formed by neutrophils and epithelial cells, were observed in BV with intermediate flora (81). Furthermore, a study has also shown increased expression of HBD-2 in vaginal epithelial cells elicited by BVAB, while no such association was found by another study (63, 82). Expression of other AMPs including SLPI and HE4 was also found to be associated with BV organisms, but their negative association were also reported (63, 83). The high levels of AMPs, including S100A8 and calprotectin, were found in lavage samples of BV cases (84). These proteins bind manganese, leading to decrease in availability of free manganese which is an absolute requirement for *lactobacilli* to grow, thus inhibiting their proliferation and creating milieu for BVAB to grow (85). Another AMP i.e., cathelicidin was also observed at high levels in BV women, acting as a pore-forming toxin to disrupt membrane of pathogenic bacteria (86, 87). Cathelicidin also induces the migration of neutrophils, macrophages, and monocytes, ultimately leading to inflammatory response against infection (88). Recently, high levels of lactoferrin, an iron binding AMP, which is predominantly produced by neutrophils, were also reported in BV women (89). Iron sequestering ability of lactoferrin leads to depletion of free iron that is required for the growth by BVAB. The elevated levels of α-defensins, lactoferrin, and cathelicidin in BV suggest the possibility of high neutrophils levels in BV, however, no such elevation has been observed (69, 90).
Kalia et al. Immunomodulation in RVVI

FIGURE 1 | Immunopathology of Bacterial Vaginosis (BV). BV induces milieu enriched with proinflammatory cytokines and antimicrobial peptides (AMPs) in vagina. This enriched vaginal milieu has been induced by recognition of BV associated bacteria (BVAB) by pattern recognition receptors (PRR) such as the TLR4, MBL, and C3. The role of these cytokines and AMPs is to induce migration of neutrophils, macrophages, and monocytes. However, no such migration has been reported in BV, depicting the inferior inflammatory response without any localized inflammatory symptoms. Conversely, persistent BV has been shown to lead chronic and extreme vaginal inflammation, while the role of adaptive immunity is still elusive.

On the other hand, DCs maturation has been shown to be induced by lavage samples from women with BV leading to DC-surface expression of CD83 and CD86 markers, reduced internalization ability, improved antigen presentation to T cells, thereby modulating T cell responses (91). The same profile of activation and maturation of DCs and T cells has been reported recently but found to occur only at the highest G. vaginalis concentration (92). No heightened neutrophils levels and maturation of DCs only at high bacterial concentration depicts the uncharacteristic and poor inflammatory response without any localized inflammatory symptoms, perhaps the reason why BV is not called bacterial vaginitis. However, very recently a longitudinal study has shown occurrence of chronic and extreme vaginal inflammation due to persistent BV (59). Overall, these studies confirm the inflammatory nature of BV. Absence of local inflammatory responses can be attributed to evasion of BVAB or perhaps the presence of genetic polymorphisms in inflammatory genes modifying the inflammatory responses.

Immunity in VVC

Unlike BV, where the host immediately recognize and generate immune responses against BV associated bacteria, which are the different entities from the normally present Lactobacilli, VVC involves the same entity Candida, present both as commensal as well as responsible for pathogenesis. The pathogenic activity of Candida is determined by its morphology, where the yeast form is associated with commensalism, and hyphal form with pathogenicity. The detection and elimination of Candida pathogenic form is mediated by vaginal epithelial cells, the first barrier encountered by pathogen (93). Vaginal epithelial cells “sense” the danger constituted by the pathogen and respond by immune cell activation, secretion of inflammatory immune mediators and by generating immune responses. The danger can be attributed to virulence factors secreted by Candida hyphae e.g., secreted aspartic proteases (Saps). Saps can directly lead to neutrophils recruitment at the site of infection (94). However, a new protease, namely Candidalysin, has recently been proposed to be secreted by Candida hyphae (95). This protease is the first protein toxin recognized in any human fungal pathogen that damages the epithelial cells and thus triggers host immune responses. Candidalysin has recently been proposed as a key hypha-associated virulence factor responsible for immunopathogenesis of VVC (96). By sensing candidalysin activity, vaginal epithelial cells respond to pathogenic C. albicans through activation of two signaling pathways i.e., p38/c-Fos and MKP1 pathways (95, 96). The same pathways have been suggested as common mechanism facilitating different human epithelial cells for differentiating pathogenic Candida from non-pathogenic yeast form and to coordinate innate immune responses (93, 97). The receptors employed by epithelial cells to sense candidalysin activity are still pending to be elucidated. The resulted activation of p38/c-Fos and MKP1 signaling pathways persuades expression of pro-inflammatory cytokines and AMPs including IL-1α, IL-1β, IL-8, G-CSF, GM-CSF, β-defensin 3, CCL20, S100A8, and S100A9 from vaginal epithelial cells, which are instrumental for innate immune cells recruitment (95–97). Vaginal epithelial cells were shown to produce calcium-binding proteins namely S100A8 and S100A9 in response to C. albicans.
that lead to robust neutrophils migration during VVC (98, 99). However, their involvement was not found to be crucial for driving the neutrophils response in VVC (100).

Neutrophils and macrophages are the first innate immune cells that recruit at the site of infection in response to affected epithelial cells derived immune mediators. The neutrophils further release TNF-α that consequently up-regulates TLR4 expression on epithelial cells (101). Independent to these virulence factors and cytokines response, direct contact mediated recognition of C. albicans sugar moieties such as mannann and β-glucan is mediated by neutrophils, macrophages, and dendritic cells via surface PRRs including TLRs (including TLR 2, 4, and 9) and CLRs (including MBL, Dectin-1, Dectin-2, DC-SIGN, and MinCle) (40, 102, 103). Ligation of PRRs further stimulate downstream MAPK and Syk signaling, production of NF-kB, and pro-inflammatory cytokines. The activated immune cells form a loop of positive feedback that amplifies the inflammatory process, leading to ultimate effector functions. Other than this, immunofluorescence analysis of the Candida hyphae from VVC patients showed the presence of C3 and pH dependent binding of MBL suggesting their direct role in Candida recognition and activation of alternative as well as lectin complement pathways (40, 102). In addition, MBL have been shown to cause agglutination of Candida upon hyphae generation independent of direct/indirect opsonophagocytosis and complement activation (104). In consonance, two different studies have reported high MBL levels in women with VVC than healthy women, suggesting the active role of MBL in the defense against VVC (105, 106). Other complementary evidences have shown that low MBL levels in women predispose them to VVC (55, 107, 108).

Moreover, neutrophils, through direct contact via PRRs particularly CLRs, mediate killing of Candida with short hyphae intracellularly and those with long hyphae extracellularly. The intracellular killing is mediated by phagocytosis while, extracellular killing is mediated by NETosis i.e., development of neutrophils extracellular traps (NETs). Both mechanisms involve oxidative burst due to reactive oxygen species (ROS) production (109–113). Additionally, autophagy, fibronectin, release of granular enzymes, AMPs including calprotectin and Dectin-1 signaling has also been shown to be involved in NETosis (109, 110, 112, 114, 115). In contrast, some other studies suggested that β-glucan mediated NETosis occurs through complement receptor 3 (CD11b/CD18) and not through Dectin-1 signaling or ROS mechanism, indicating their controversial role in NETosis (111, 114). Furthermore, recruitment of polymorphonuclear neutrophils (PMN) into vagina was observed to be associated with vaginal inflammatory symptoms when volunteer women were challenged with live C. albicans (116). This vaginal inflammation was observed to decrease with diminution of PMNs (117, 118). Robust response by neutrophils recruitment correlates well with local vaginal inflammation similar to high vaginal Candida burden for causing VVC. However, a mechanism explaining PMN dysfunction at the vaginal mucosa remained a mystery. The most current information relative the mechanism(s) of the VVC immunopathogenesis where a strong inflammatory condition occurs (via candidialysin and hyphal morphology transition), but fail to reduce the Candida load and thus the persistence of infections has been proposed (119). This has recently been termed as “neutrophil anergy” and involves vaginal factors that inhibit the ability of the PMN to bind to Candida for effective killing (119). Unlike neutrophils, macrophages mediate only intracellular killing of Candida but both through ROS and RNS mechanisms (120).

Just like surface PRRs, the intracellular PRR i.e., NLRs of innate immune cells are also activated by DAMPs or through direct contact of internalized pathogenic fungal components that activate NLRP3 inflammasome, consequently leading to release of proinflammatory cytokines including IL-1β and IL-18 (121). This inflammasome activation also led to programmed host cell death known as pyroptosis, which is employed as one of the evasion strategies by virulent Candida for escaping macrophages (122, 123). Owing to this reason, the macrophages mediated killing of intracellular C. albicans is shown to be of lower efficiency than neutrophils (103, 121). However, the fungal triggers activating the inflammasome mediated pyroptosis are still not known. Finally, IL-1β and IL-18 release through inflammasome activation by innate immune cells promote adaptive T helper 17 (Th17) and Th1 responses respectively, thus linking innate with adaptive immunity (124). Moreover, both in vitro and in vivo studies have shown that Dectin-1-Syk-CARD9 signaling couple innate and adaptive immunity independently of TLR signals and induce differentiation of adaptive Th-17 and Th-1 cells (125, 126).

Carvalho and group showed that Dectin-1 is necessary for controlling vaginal infections (127). The study evaluated two genetically distinct strains of mice with vaginal candidiasis for Dectin-1 deficiency and showed that the role of Dectin-1 in antifungal immunity lies ahead of Th17 cell activation and is significantly dependent on host genetic milieu. The study found that Dectin-1 was required for appropriate control of vaginal candidiasis in mice strain C57BL/6, but not in BALB/c mice. The former Dectin-1 deficient strain of mice was found to be vulnerable to infection, with defective production of cytokines including IL-17A as well as IL-22 and adaptive Th1 responses, relative to reverse effect observed in latter strain. However, this depiction of two tremendously contradictory phenotypes, have been attributed to differential expression of functionally distinct Dectin-1 isoforms by two strains (128). Thus, the study clearly depicts that Dectin-1 essentially contributes to the stability of Th1, Th17, Treg CD4+ T-cell populations during infection, as its deficiency lead to defective release of Th17 cells in C57BL/6 mice and both Th1 as well as Treg cells in BALB/c mice after infection. This suggests the contribution of Dectin-1 in differentiation of T helper cells and its relative ability to control the vaginal infection. In consonance to this, another study highlighted the specific role of Dectin-1 in VVC in four women from Netherlands, affected either by onychomycosis or RVVC (129). The Dectin-1 expression in these women was found to be poor with defective β-glucan binding, defective Th17 responses, and defective production of cytokines including IL-6, TNF-α, and IL-17. Another study has shown increased intracellular expression of Dectin-1 in response to opsonised Candida albicans through recognition of β-1,3-glucan (130).
In consonance, a recent study found significantly high serum Dectin-1 levels in VVC cases relative to controls suggesting the active role played by Dectin-1 in defense against VVC (57). Thus, Dectin-1 is certainly a formidable PRR for providing systemic immune defense against the infection however, its role as a mucosal defense marker is still ambiguous due to inconclusive literature regarding its normal expression on vaginal mucosa as aforementioned. Therefore, caution should be taken regarding these interpretations. Moreover, two studies based on different animal models (rat and mouse) of VVC, have depicted the controversial role of dendritic cells following infection with no definite conclusion (131, 132).

The activated Th17 cells release IL-17, a multifunctional pro-inflammatory cytokine, that further increases expression of PMNs, chemotactic cytokines and AMPs (HBD-2/3, histatins), promoting effective inflammatory response (133–135). Studies have shown that inhibition of Th17 cells differentiation led to considerable decrease in production of IL-17 and HBD-2 with consequent exacerbation of VVC (136–138). However, some studies have suggested that inflammatory response during VVC occurs independently of Th17 cell lineage (99, 139, 140). Hence, valuable information relative to adaptive T cell-mediated immunity (CMI) remained elusive as almost equal number of studies are recommending and contrasting its role in VVC. Additionally, studies have also established the link between acquired antibody mediated humoral immunity (HI) with CMI against VVC, suggesting the existence of protective antibodies but at lower concentrations with no appreciable protection (141–143). A common misbelieve regarding IL-17 is that, it is only produced by adaptive Th17 cells and thus function mainly in the adaptive immunity. However, an array of innate immune cells called “innate Type 17” cells also produces IL-17. These cells include innate lymphoid cell type 3 (ILC3), natural killer T (NKT) cells, γδT cells, and TCRβ+ “natural” Th17 cells (nTh17) (144–146). Furthermore, contrasting data regarding neutrophils as a source of IL-17 has also been documented (147, 148). However, as aforementioned, CARD9, an adapter that mediates Dectin-1 signaling, is essential for adaptive IL-17 response but this adaptor was not shown to be involved in innate IL-17 responses (126). Recently, a study reported Candidalysin mediated innate IL-17 response in murine model of oral candidiasis (149). However, the role of IL-17 production by innate type 17 cells in VVC is largely uncharted. Overall, these studies highlight the role of innate immunity that work in concurrence with vaginal epithelial cells against VVC, while, the role of adaptive immunity is still elusive (Figure 2).

**Immunity in TV**

The innate immunity against *T. vaginalis* involves PRRs stimulation, phagocytes recruitment in vagina and complement activation (150–154). The first barrier of innate immunity encountered by pathogens is vaginal epithelial cells, that lead to immune response generation by TLRs (TLR2, TLR4, and TLR9) expression via p38 MAPK signaling pathway, consequently leading to IL-8 and TNF-α release from vaginal epithelium (155, 156). However, ligands of *T. vaginalis* that bind to these TLRs have not been identified till date. Alternatively, independent of these TLRs expression, the lipophosphoglycan (LPG), a major component of *T. vaginalis* membrane, also induces inflammatory response by release of pro-inflammatory cytokines after contacting human vaginal epithelial cells (157). In addition, galectin-1 and galectin-3 expressed by vaginal epithelial cells were reported as receptors for *T. vaginalis* LPG (158, 159). Galectin-3 was accounted for pro-inflammatory cytokines (IL-8 and MIP-3α) release whereas galectin-1 was shown to play immunosuppressive role that might help in parasites evasion. Both, IL-8 and MIP-3α cytokines show chemotactic activity, promote migration of immune cells particularly neutrophils and other phagocytes across the endothelium, while, MIP-3α also induces dendritic cell maturation (146). Moreover, *T. vaginalis* also releases leukotriene B4 (LTB4), an endogenous lipid, which leads to inflammation in women infected with *T. vaginalis* due to its leukocytes chemotactic activity (160, 161). This lipid mediator induces the release of IL-8, ROS, and AMPs including β-defensin-3 and cathelicidin (LL-37) through binding to its receptors BLT1 and BLT2 on immune cells (162). The immune cells that are predominantly found in the vaginal secretions of *T. vaginalis* infected patients are neutrophils (163). In response to *T. vaginalis* stimulation, immune cells release pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α, leading to neutrophils recruitment, explaining its predominant accumulation for mediating initial inflammatory response following TV (161, 164, 165). These neutrophils achieve *T. vaginalis* killing by phagocytosis and by novel mechanism i.e., taking *T. vaginalis* “bites” prior to parasite death, using trekocytes (166). Immune-fluorescence analysis of the *T. vaginalis* revealed binding of MBL to its surface carbohydrates i.e., unmodified N-glycans (153). MBL binding to *T. vaginalis* have shown to cause self-aggregation of parasites, lowering their motility and division rate (153). *T. vaginalis* also leads to the activation of complement system, encouraging killing through neutrophil-mediated endocytosis (150, 151, 153). Furthermore, SLPI, an AMP, has also shown to be associated with TV (167).

Moreover, TV was found to induce CD4+ T cells penetration in vaginal tissues indicating the role of T-cell mediated adaptive immunity in defense against TV (168). In support of this, a study reported the involvement of Th1 triggered cytokines (IL-2 and IFN-γ) in maintaining low burden of *T. vaginalis* infection (169). Similarly, the elevated levels of Th17 triggered IL-17 and Th22 triggered IL-22 were found in women with Trichomoniasis (170). Furthermore, elevated expression of cytokines including IL-6 and TNF-α, that induces the differentiation of Th22 cells, were reported in *T. vaginalis* activated macrophages (165). Both, IL-22 and IL-17 share common functional aspects and were shown to collaboratively induce and up-regulate production of an AMP named cathelicidin (LL-37) (170–172). All these cytokines produced by different subsets of Th cells collectively lead to the activation and migration of effectors cells including neutrophils, macrophages, cytotoxic T lymphocytes, natural killer cells, along with differentiation of B cells into antibody producing plasma B cells (173). However, the exact role of these different subtypes of Th cells in TV is still remains to be elucidated. *T. vaginalis* infection also leads to the induction
Immunopathology of vulvovaginal candidiasis (VVC). Vaginal epithelial cells respond to pathogenic form of *Candida* either through direct contact via pattern recognition receptors (PRRs) or by sensing hypha associated virulence factor e.g., Candidalysin, through unknown receptor, further activating two signaling pathways i.e., p38/c-Fos and MKP1. The response includes immune cell activation, secretion of inflammatory immune mediators, which are instrumental for innate immune cells recruitment. Neutrophils and macrophages are the first to recruit at the site of infection. The neutrophils release TNF-α that provides shield from infection by up-regulating TLR4 expression on epithelial cells. The expressed PRRs on ligation with pathogen further stimulate downstream signaling, production of NF-κB and pro-inflammatory cytokines, forming a loop of positive feedback. The effector cells mediate killing of *Candida* with short hyphae by phagocytosis and those with long hyphae by NETosis. Both mechanisms involve reactive oxygen species (ROS) production that further regulates all the stages of inflammation. The phagocytised pathogenic components activate NLRP3 inflammasome through intracellular NLRs, and lead pro-inflammatory cytokines release including IL-1β and IL-18, which further promote adaptive T helper 17 (Th17) and Th1 responses respectively, thus linking innate with adaptive immunity. Independently of this, Dectin-1-Syk-CARD9 signaling also couple innate and adaptive immunity and induce differentiation of adaptive Th-17 and Th-1 cells. The activated Th17 cells release IL-17, which further increases expression of PMNs, chemotactic cytokines and AMPs, promoting extreme vaginal inflammation. However, an array of innate immune cells called “innate Type 17” cells also produces IL-17. Thus, valuable information relative to adaptive T cell-mediated immunity (CMI) remained elusive in VVC.

HOST DEFENSE AGAINST RVVI LEADS TO OXIDATIVE STRESS

A wide range of substances, known as reactive oxidants, consisting of free radicals and other non-radical oxygen derivatives, are constantly generated as an essential part of metabolism. These reactive oxidants are further neutralized by an array of protective antioxidant mechanisms occurring in human system and thus maintains redox homeostasis (180). An imbalance between oxidants and antioxidants, due to an excess oxidants production, leads to oxidative stress that disrupts redox homeostasis (180). From the past decade, evidences have emerged that suggested, reactive oxidants also generate as an integral part of defense mechanism, leading to the state of oxidative stress with significant biological consequences and
Immunopathology of Trichomoniasis (TV). T. vaginalis through unknown ligand lead to immune response generation by pattern recognition receptors (PRRs including TLR2, TLR4, and TLR9) via p38 MAPK signaling pathway, consequently leading to IL-8 and TNF-α release from vaginal epithelium. Independent of this, Galectin-1 and Galectin-3 expressed by vaginal epithelial cells recognize T. vaginalis LPG, wherein Galectin-3 accounts for pro-inflammatory cytokines (IL-8 and MIP-3α) release. The pro-inflammatory cytokines promote recruitment and migration of immune cells, with predominant accumulation of neutrophils. The neutrophils achieve T. vaginalis killing either by phagocytosis or by novel mechanism i.e. taking T. vaginalis “bites” prior to parasite death, using trogocytosis. T. vaginalis also leads to the activation of complement system, encouraging killing through neutrophil-mediated phagocytosis. Phagocytosis involves reactive oxygen species (ROS) production that further regulates all stages of inflammation. The phagocytosed pathogenic components activate NLRP3 inflammasome, which further link innate with adaptive immunity, promoting adaptive CD4+ T cells response. The different subsets of Th cells trigger cytokines that collectively lead to the activation and migration of effectors cells promoting extreme vaginal inflammation, along with differentiation of B cells into T. vaginalis-specific antibody producing plasma B cells.

These reactive oxidants affect all the stages of the inflammatory immune response, starting from the release of DAMPs, their sensing by PRRs, activation of signaling pathways, release of immune mediators, and initiation of the innate and adaptive cellular responses to the ultimate killing of pathogens by effectors phagocytic cells as validated by different studies mentioned above and below.

Oxidative stress plays an important role in release of DAMPs such as HMGB1 in external surroundings (185–187). In turn, HMGB1 itself leads to ROS and RNS generation by stimulating cellular responses and up-regulating genes encoding iNOS via TLR4 activation (188, 189). Moreover, these oxidants also promote cells surface expression of PRRs (190, 191). In turn, activated TLR and CLR-dependent pro-inflammatory signaling, is coupled with ROS generation and up-regulated NOXs and iNOS expression (130, 185, 192, 193). Thus, TLRs and CLRs activation results into both oxidative and nitroxidative stress. These oxidants further leads to TLR engagement and activation thus contributing to the pathophysiology of diseases (181). These reactive oxidants are divided in to two main types including reactive oxygen species (ROS) and the reactive nitrogen species (RNS) (182). The former includes primary ROS namely superoxide anion radical (O₂−) and secondary ROS including hydrogen peroxide (H₂O₂) and the hydroxyl radical (OH·) generated by the action of enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) that exists in different isoforms (183). The latter includes nitrogen oxide free radical (NO·), the parent molecule of all RNS, generated by the action of enzyme NO synthase (NOS) that catalyse the conversion of l-arginine to l-citrulline in a five-electron oxidative reaction. The NOS exist in three different isoforms that includes type I-neuronal NOS (nNOS), type II-inducible NOS (iNOS), and type III-endothelial NOS (eNOS). In which iNOS is expressed only upon cell stimulation by pro-inflammatory cytokines, by pathogen and pathogen associated molecules (as given below) while nNOS and eNOS express constitutively (184).
resulting in a round of magnification, designated as the “TLR-radical cycle,” which ultimately causes chronic inflammatory response (193). Moreover, the responses generated by PRRs activation are mainly communicated through activation of NF-κB, a redox sensitive transcription factor, which is also activated by ROS. In turn, NF-κB controls the expression of genes involved in innate immunity that leads to ROS generation (194). In addition, ROS generation have also been implicated for NLRP3 activation that generate adaptive immune responses through inflammasome and also leads to further ROS generation (195, 196).

Overall, these studies suggest that both oxidative stress and inflammation stimulate each other and thus create a nasty cycle that leads to the amplification and dissemination of inflammatory response and respiratory/oxidative burst (the production of ROS). The latter is a crucial reaction that occurs in activated inflammatory cells especially neutrophils and macrophages to degrade and kill internalized pathogen by phagocytosis. That is why oxidative burst has long been recognized as a typical consequence of immune cell stimulation coupled with both chronic and acute states of inflammation (182, 197). All these inflammatory stages that lead to ROS generation are shown to be actively involved in RVVI, discussed above, suggesting the major role of oxidative stress in pathophysiology of RVVI and its contribution in vaginal immunity as an integral part of defense mechanism.

Moreover, studies have documented the ROS production by neutrophils in response to pathogenic bacteria, C. albicans and T. vaginalis infection (43, 130, 163, 198–200). Studies also documented the release of high levels of ROS by neutrophils in response to Candida species such as C. galbrata and C. dubliniensis (201, 202). The concentration of ROS in the vaginal discharge of BV patients was found to be significantly higher than that from healthy women (203). Candida species isolated from VVC patients induce ROS production in neutrophils (204). Reduced vaginal concentrations of NO metabolites were shown to increase susceptibility to recurrent episodes of VVC (205). Likewise, reduced serum concentration of ROS has been shown to increase susceptibility to RVVI (206). Other than neutrophils, macrophages were also shown to release cytotoxic NO products against T. vaginalis with increased iNOS expression (165, 207). In addition, high levels of cytotoxic NO products and increased iNOS expression was found in WBCs and vaginal lavages of T. vaginalis infected asymptomatic women relative to symptomatic women (208, 209). Thus, high ROS production plays an important role in maintaining low burden of infections, as observed in asymptomatic women depicting a strong relationship between oxidative stress and vaginal inflammation caused by RVVI.

**HIJACKING OR EXPLOITATION OF HOST IMMUNE RESPONSES BY RVVI PATHOGENS**

As discussed above, inflammation signifies an essential immune mechanism which is meant to eliminate pathogens and repair the damage caused by deleterious stimuli. However, there are conditions in which such refurbishment may not occur effectively, resulting in constant pushy cellular stress, disseminating, and magnifying the inflammatory response. In these situations, the process becomes defective, leading considerable variations in tissue functions, with persistent and systemic derangements of homeostasis (182, 210). These conditions usually occur when pathogen becomes capable of evading and subverting host immune responses, creating a niche that allows its replication and leading to continuous stimulation and thus amplification of inflammatory immune responses. Generally, the evasion mechanisms counteract different events in the entire RVVI pathogenesis, but this review will focus on the mechanisms by which pathogens subvert or manipulate the host immune responses, hijack it and use it for its own advantage.

In BV, the biota related to BV was found to inhibit the release of secondary pro-inflammatory cytokine i.e., IL-8 (69). As IL-8 endorses neutrophils migration, its absence does not allow neutrophils to enter the vagina because of which local inflammation does not occur, allowing pathogen survival. Also, BVAB were shown to release a combination of short chain fatty acids, including butrate and succinate, which modulate the host immune responses by negatively affecting neutrophils and monocytes migration in vagina and their endocytic activity (211). Moreover, lavages from women with BV as well as G. vaginalis separately found to reduce internalization ability of dendritic cells (DC) (91, 92). Additionally, BVAB has been shown to mask itself from host’s immune responses by incorporating host sialic acid produced as a result of chopping of vaginal mucosal layer by bacteria (212–214).

Similarly in VVC, C. albicans was found to down-regulate TLR4 expression on epithelial cells, thus restraining TLR4 mediated stimulation of immune responses and increasing C. albicans infection (101). Candida species has the ability to shield its β-glucan (the popular ligand of Dectin-1) with the help of its cell wall components, thus preventing its recognition by Dectin-1 and inhibiting Dectin-1 mediated immune responses (215). As mentioned above, C. albicans leads to the activation of complement (C) system and thus generate host immune responses against pathogens. However, the pathogen employs different strategies to evade the classical and alternative pathways of C system. The first strategy includes degradation of host complement components including C3b, C4b, and C5 (216). Second involves surface acquisition of host complement inhibitors or regulators involving plasminogen-binding surface protein, factor H, C4b-binding protein (C4BP), and FHL-1. These surface attached inhibitors sustain their regulatory property and inactivate respective host C proteins (217–219). The third strategy includes direct and indirect C inhibition by self secreting inhibitory protein including pH-regulated Ag 1 (Pra1). This protein either directly blocks the activation and conversion of C3 or indirectly inhibits C system by binding to the host C inhibitor proteins (factor H and C4BP) (220–222). Candida also inhibits the terminal complement complex (TCC) formation by secreting Saps proteins (216).

Alternatively, C. albicans was shown to inhibit phagolysosomes formation, which is an important step in
the process of killing of a pathogen (223). Moreover, pyroptosis is a host antimicrobial response mechanism that involves death of host cells infected with intracellular pathogens. This mechanism has been shown to be hijacked by highly virulent *Candida* strain, for escaping the host immune cells, particularly macrophages, thus mediating its own survival and host cell killing (122, 123, 224, 225). As afore-discussed oxidative stress plays a fundamental role in host defense against RVVI. However, *Candida* has strategies to neutralize and evade the oxidative stress. *C. albicans* expresses superoxide dismutase (SODs) and other antioxidant enzymes on the cell surface. These extracellular SODs also have vital roles in the detoxification of superoxide radicals generated by phagocytes and hence prevent massive ROS accumulation (226, 227). In addition *C. albicans* catalase and vacuole (fungal organelle) formation has been suggested to counteract oxidative stress (228–230). Moreover, *C. albicans* also exploit host cytokine production for its own benefit by inhibiting host IL-12, IL-17, and IFNγ production (231–234). These cytokines are critical for host innate and adaptive immunity as studied above.

Similarly, *T. vaginalis* uses DCs and macrophages for its own advantage by modulating their immune responses leading to reduced synthesis of IL-12 and increase synthesis of IL-10 and TGF-β (235, 236). Furthermore, NF-κB was also shown to be inhibited by *T. vaginalis*, further suppressing the expression of pro-inflammatory genes including IL-12, suggesting the modulation of the host cytokines milieu as an effective immune evasion strategy followed by *T. vaginalis* (235). Other than this, cysteine proteases secreted by *T. vaginalis* helps in evasion of host's immune responses by degrading its various components that includes subclasses of host antibodies (IgG and IgA), C3 opsonin and secretory leukocyte protease inhibitor (SLPI), an antimicrobial peptide (178, 179, 237–239). The cysteine proteases also contribute to cytotoxicity particularly against B cells (240, 241). Killing of B cells and phagocytosis of human peripheral blood mononuclear cells (PBMCs) through contact dependent manner by *T. vaginalis* have also been reported (242, 243). This parasite neutralize specific host antibodies by secreting numerous immunogenic soluble antigens, thereby evading host immune responses (244–246). Additionally, *T. vaginalis* has been suggested to incorporate host serum proteins in its surface, masking itself from host's immune responses (247). Taking this into consideration, recently it was proposed that *T. vaginalis* acquire CD59 from host cells, e.g., red blood cells (RBCs), thereby evading itself from host complement mediated killing (248).

As mentioned above, galectin-1 and galectin-3 receptors expressed on vaginal epithelial cells surface, bind to LPG core of *T. vaginalis* (158, 159). The binding of *T. vaginalis* to galectin-1 plays an immunosuppressive role by inhibiting the releases of IL-8, MIP-3α, and RANTES, the chemokines that connect innate and adaptive immunity and facilitate the recruitment of phagocytes, another important evasion strategy by the pathogen (159). This suggests that in response to *T. vaginalis* infection, the two molecules of same family play contrasting role. However, in general, galectin-1 can also play immunostimulatory role while galectin-3 is also capable of down-regulating the inflammation (249, 250). The possible explanation behind this inconsistency could be recognition of self ligands on host cell surface by galectins, the reason behind why galectins are still not strictly considered as PRRs, because PRRs recognize only highly conserved pathogen associated structure that are not present in host (251). This obvious contradiction divulgus our incomplete understanding regarding the structural and biophysical features of ligand binding preferences displayed by galectins and genuine variety in identification of the host galectin range (252). However, the details of this topic are outside the scope of this review. Moreover, *T. vaginalis* can lead to apoptosis of neutrophils and macrophages by reducing expression of the anti-apoptotic proteins and by activating caspase-3, which is a pro-apoptotic marker (253, 254). Other than this, like many other parasites, *T. vaginalis* also releases extracellular vesicles, for instance exosomes, which can also modulate the host immune responses by diminishing vaginal IL-17 concentration and up-regulating IL-10 expression in macrophages (255). Besides this, the surface immunogens of *T. vaginalis*, involving P230 and P270 go through conformational changes that prevent the epitope accessibility for binding of host antibodies that allows parasite to evade host humoral immune responses (256, 257). Thus, understanding the molecular mechanisms employed by pathogens to exploit the host immune response for its own benefits is of crucial importance for the management of these devastating infections.

**IMMUNOPATHOGENESIS OF RVVI: PROPOSED THEORY**

Vaginal innate immunity is the first line of defense system that responds to the pathogens and activates the adaptive immunity. In turn, activation of adaptive immune responses also support the function of innate immunity consequently forming a loop of positive feedback, leading to amplified inflammatory responses and augmented effector functions for the ultimate killing of the pathogens. This emphasize on the pivotal role of innate immunity, whose impairment can lead to adaptive immune dysfunction and increased susceptibility to infections. Women inspite of having disturbances in vaginal milieu represent different clinical outcomes. Asymptomatic cases of RVVI is due to proper functioning of both innate and adaptive immune system, that have successfully coped up with the infection in spite of different evasion strategies followed by the pathogens and thus asymptomatic cases should be considered as healthy individuals. While symptomatic cases are characterized by the impairment in the communication part of the innate immunity that signal for the activation of host adaptive immune responses thus, breaking the loop of feedback amplification. This increases the chances of hijacking and evasion of the immune system by the pathogen, which creates a niche for the pathogen replication, leading to continuous stimulation and violent innate immune responses. Thus, symptoms that define the infection are due to robust inflammatory immune responses and high vaginal pathogen burden—a fine interplay that determines the clinical outcome of infection. However, the presence of symptomatic RVVI is appeared to be more dependent on host factors rather
than on pathogens itself. Therefore, treatment should depend upon recognition of the impaired unit of innate immunity that do not allow adaptive immunity to respond and thus increasing susceptibility to vaginal infections. These most probable impaired innate immune units could be PRRs that signal for activation of adaptive immune responses. The genetic variations in these PRRs have been shown to play an important role in how a woman responds to a particular microbial challenge, as evidenced by several genetic disease association studies given below. Thus, looking at the women itself provided the answer to the major query suggesting that symptomatic/asymptomatic cases of RVVI are due to differences in women’s immunity, conferred partially or wholly by genetic variations.

**GENETIC SUSCEPTIBILITY: HOST GENOTYPE MODULATES IMMUNE RESPONSES AND VULNERABILITY TO RVVI**

Genetic variations, particularly single nucleotide polymorphisms (SNPs), in genes coding various components of immune system have evidently been shown to modulate innate and acquired antimicrobial immune responses, both qualitatively and quantitatively. These SNPs affect gene expression as well as function and hence modulates individual’s susceptibility to acquire diseases including RVVI, as evidence by several studies (Table 1). SNPs in genes coding cytokines, enzymes, growth factor, PRRs, and signaling adaptors were found to be associated with RVVI susceptibility. A study have shown association of dull IL-1β response against pathogens in allele 2 IL1RN*2 carriers resulted due to polymorphism in intron 2 (IL1RN) of interleukin-1 receptor antagonist gene (IL-1Ra), widely known to modulates the pro-inflammatory action of IL-1 gene (258). Similarly, immunomodulatory effect of IL1β polymorphisms was shown to be associated with susceptibility of acquiring BV (259, 260). Another study showed increased susceptibility to RVVC due to reduced levels of vaginal antcandidal factors in IL-4 polymorphism homozygotes carriers (205). Also, polymorphisms in IL-6 were associated with reduced cytokine responses, conferring increased risk to BV and premature deliveries (260, 261). However, IL-8 polymorphism was shown to be associated with increased cytokine responses and decreases BV risk (260). Presence of polymorphisms in tumor necrosis factor-α (TNF-α) in BV women were associated with increased vaginal TNF-α levels and preterm deliveries (262, 263). Another study showed association of increased BV risk as well as pre-term delivery with polymorphisms in protein kinase C alpha (PRKCA) and fms-like tyrosine kinase 1 (FLT1) genes involved in the regulation of inflammatory responses (261). Corticotropin-releasing hormone (CRH) is involved in stress and regulation of inflammatory immune responses. Polymorphisms in genes coding for Corticotropin-releasing hormone binding protein (CRH-BP), Corticotropin-releasing hormone (CRH) and corticotropin-releasing hormone receptor 2 (CRH-R2) were found to be associated with BV (264). Functional polymorphism at position 677 in gene coding for methylene tetrahydrofolate reductase (MTHFR), a rate limiting enzyme in methyl cycle, was shown to alter MTHFR activity and DNA methylation in human placenta, which further increases 3.5-fold risk of premature rupture of membranes in BV positive women (265).

As discussed above, PRRs are the important dictatorial components of immune system. Polymorphisms in gene encoding PRRs including TLRs (TLR2, TLR4, TLR7, and TLR9), NLR (CIAS1), and CLR (MBL2 and CLEC7A) have been shown to modulate immune responses and susceptibility to RVVI. Studies have shown association of TLR2 polymorphisms with 3-fold increased risk of acquiring BV and increased colonization of BVAB (266, 268). In consonance, a non-synonymous SNP (nsSNP) in TLR2 was linked with defective protein function, which subsequently reduced the production of pro-inflammatory cytokines and predisposition to RVVC (269). Similarly, polymorphisms in TLR4, TLR7, and TLR9 were shown to be associated with increased risk of BV and >10-fold increased colonization of BVAB (71, 267, 268). In contrast, a study has shown decreased risk of acquiring BV with TLR2 and TLR7 Polymorphisms (267). Additionally, polymorphism in NLRP3 gene, also known as cold-induced auto-inflammatory syndrome 1 (CIAS1) gene, which code for the inflammasome component NLRP3, has been shown to cause impaired NLRP3 expression and IL-1β production that subsequently predisposes women to RVVC (270). Moreover, polymorphisms in genes involving MBL2 and CLEC7A have been shown to modulate their encoded CLR expression and activity resulting in defective immune responses and altered susceptibility to RVVI (55, 57, 107, 108, 129, 271–273). Studies have shown an association of MBL2 codon 54 polymorphisms with increased RVVC risk (107, 271, 272). Another study has found an association of codon 54 polymorphism with increased risk of both RVVC and RBV (273). Moreover, Y/X promoter polymorphism of MBL2 was found to predispose women to RVVI either it is BV, VVC, or MI in North Indian population (55). A study identified and explained a CLEC7A nsSNP i.e., Y238X (rs16910526) in antiinfluenal defenses in onychomycosis and RVVC (129). The study showed poor expression of mutated form of Dectin-1, with defective β-glucan binding, defective Th17 responses, and defective production of cytokines including IL-6, TNF, and IL-17, alluring the cause of VVC in these patients. Moreover, Y238X variant was depicted to show gene-dose effects i.e., onset of disease at early age of 10–12 years was observed in homozygous variant daughter relative to late onset at age of 40 and 55 years in heterozygous mother and father, respectively (129). Recently, another study has reported that G allele of CLEC7A rs3901533 intronic variant and its homozygous carriers significantly lower the risk of developing RVVI and its types i.e., BV, VVC, or MI in North Indian population (57). Furthermore, a variation (Q295X) in CARD9, coding for adaptor (CARD9) that mediates Dectin-1 signaling, was shown to impair Dectin-1 signaling, resulting in decreased numbers of interleukin-17 producing effector Th17 cells and increased risk of RVVC (276). In addition, precision in diagnosing RVVI and subject assortment lead to variations between studies that limit the simplification of the reported findings to other populations.
### TABLE 1 | Human genes conferring susceptibility to RVVI.

| Genes | SNP(s) | Associated phenotype observed | RVVI |
|-------|--------|--------------------------------|------|
| **IL-1ra** | IL1RN*2 | Reduced IL-1β response | Increased colonization of anaerobic Gram-negative rods, Mycoplasma, and Peptostreptococci and Decreased Lactobacilli colonization |
| **IL-1β** | −511 and +3954; +3954 | Increased cytokine response | Increased risk for BV |
| **IL-4** | rs2243250 (−589T/C) | Increased vaginal IL-4, reduced NO and MBL levels | Increased risk for RVVC |
| **IL-6** | −174; rs1800795 | Reduced cytokine response | Increased risk for BV |
| **IL-8** | −845 | Increased cytokine response | Decreased risk for BV and High spontaneous preterm delivery |
| **TNF-a** | TNF-2 (−308) | Elevated levels of vaginal TNF-α | BV and Increased risk of spontaneous preterm birth |
| **PRKCA** | rs1003599, rs10491202, rs11688528, rs104760112, rs17762314, and rs1990503 | – | BV and High spontaneous preterm delivery |
| **FLT1** | rs748252 | – | – |
| **CRH-BP** | +17487 | – | BV |
| **CRH** | + 3362 and −1667; +8288, +5253, and + 4853 | – | Increased risk for BV |
| **CRH-R2** | +8288, +5253, and + 4853 | – | – |
| **MTHFR** | C677T | Altered MTHFR enzyme activity, Affect DNA methylation in the human placenta | BV and increased risk of premature rupture of fetal membranes |
| **TLR2** | rs1898830, rs1898830, rs11938228, rs3804099 | – | 3 fold increased rate of BV/intermediate flora |
| **TLR4** | rs3804099; rs1898830; rs5743704 (P631H) | Decreased risk of BV; Deleterious effects on protein function; reduces production of IL-17 and IFNγ | Increased colonization of endometrial anaerobic gram-negative rods, anaerobic non-pigmented Gram-negative rods, anaerobic Gram-positive cocci |
| **TLR7** | rs5743737 and rs1634323; rs179012; rs187084 | – | Increased risk of BV |
| **TLR9** | rs187084 | – | Increased risk of BV |
| **CIAS1** | Tandem repeat in intron 4 | Impaired NLRP3 expression and IL-1β production | Reduced vaginal IL-1β and IL-1α levels |
| **MBL2** | Codon 54 (rs1800450); Y/X(rs7096206); rs10824792; rs10824792; rs7084554 and rs38014597 | Low MBL levels in cervico-vaginal fluids | Increased risk of RVVC |
| **Y/X** | rs10824792 | Low sMBL levels | Increased risk of both RBV and RVVC |
| **rs7084554 and rs38014597** | Low MBL levels | Increased risk of RVVI either it is BV, VVC or MI |
| **CLEC7A** | rs16910526 (Y238X) | Poor dectin-1 expression, defective ligand binding, defective immune responses | Increased risk of RVVC |
| **rs3901533** | High dectin-1 levels | Decreased risk of RVVI either it is BV, VVC, or MI |
| **CARD9** | Q295X | Decreased proportion of Th17 cells | RVVC |

*represented either by rs number, position or by possible allele. See text for required abbreviations.
RESEARCH DIRECTIONS

Though, understanding regarding immunopathology of recurrent vulvovaginal infections has broadened recently, still there are many key questions that are needed to be addressed.

First, unlike VVC and TV, studies have provided no relevant evidence for neutrophils elevation in BV, though evidences regarding high levels of bio-markers including cathelicidin that induces neutrophils migration in BV is present (88, 89).

Second, candidalysin has recently been proposed as a key hypha-associated virulence factor responsible for immunopathogenesis of VVC (96). However, the receptors employed by epithelial cells to sense candidalysin activity are still pending to be elucidated.

Third, pyroptosis is employed as one of the evasion strategies by virulent Candida for escaping macrophages (122, 123). However, the fungal triggers activating the inflammasome mediated pyroptosis are still not known.

Fourth, both in vitro and in vivo studies in VVC have shown that Dectin-1-Syk-CARD9 signaling, couple innate and adaptive immunity independently of TLR signals and induce differentiation of adaptive Th-17 and Th-1 cells (125, 126). However, no such role of Dectin-1 has been reported in BV and TV till date. Though, its role in defense and recognition of these pathogens has been revealed (277, 278). However, these pathogens do not possess β-glucans, suggesting the possibility of other ligands of Dectin-1 that are still not identified.

Fifth, an array of innate immune cells called “innate Type 17” cells have also been shown to produces IL-17 (144–146). Recently, a study reported candidalysin mediated innate IL-17 response in murine model of oral candidiasis (149). However, the role of IL-17 production by innate type 17 cells in BV, VVC, and TV is largely uncharted.

Sixth, the first barrier of innate immunity encountered by pathogens is vaginal epithelial cells that lead to immune response generation by TLRs (155, 156). However, ligands of T. vaginalis that bind to these TLRs have not been identified till date.

Seventh, the odds of hijacking increases, due to impaired immune responses, the net magnitude of which is the result of numerous genetic variations, present in multiple host genes, detailed in this review. However, so far, the functional consequences of genetic variations of only two genes i.e., MBL2 and CLEC7A have been reported, while the role of other associated genetic polymorphisms are still pending to be elucidated.

Finally, valuable information relative to the role of adaptive immunity in RVVI is still not clear, though elucidated better in TV than VVC and BV.

TREATMENT STRATEGIES

Advancements in diagnostic tools as well as drugs, targeting the pathogens, provide temporarily relief, as the infection re-occurs because disturbance in host genetic system is still persisting that must be rectified in order to restore host homeostasis. The afore-highlighted causal factors, that modulate propensity to RVVI in women, may further be used to develop efficient diagnosis and treatment strategies of this enigmatic disease. As for instance,

MBL Replacement Therapy
Plasma-derived MBL replacement has become a safe and efficacious therapeutic option in diseases associated with low MBL levels (279–281). Therefore, the emerging MBL substitution therapy could possibly be the future treatment strategy for RVVI (282).

Adoptive T-Cell Therapy
The use of CD8+, CD4+, and γδ T cells for the treatment of infections diseases and cancer has been reported to safe and efficacious (283). Therefore, the emerging MBL substitution adoptive T-Cell therapy could possibly be the future treatment strategy for RVVI.

Antibody-Based Therapy
Presence of many licensed monoclonal antibodies for the treatment of infectious diseases including HIV (284) outlines the prospects of this therapy for RVVI.

CONCLUSIONS
The methodical scrutiny of literature indicated RVVI as a multifarious disease, requiring a “perfect storm” to start infection. This “perfect storm” is a result of fine interplay between host VMB, host genotype and other local risk factors
that culminate into symptomatic infection (Figure 4). However, the presence of symptomatic RVV1 is appeared to be more dependent on host factors rather than on pathogens itself. Thus, by understanding the role of the host immune responses in disease etiology, modern research has clarified a major hypothesis shift in the philosophy of RVV1 pathogenesis. Future research in explication of highlighted critical questions may provide complete understanding of immunopathological mechanisms of RVV1. Future research in explication of the highlighted causal factors, that modulate propensity to RVV1 in women, may reveal new biologicals for preventing and treating RVV1.

REFERENCES

1. Koenig M, Jejeebhoy S, Singh S, Srídhár S. Investigating women’s gynaecological morbidity in India: Not just another KAP survey. Reprod Health Matters. (1998) 6:84–97. doi: 10.1016/S0968-8080(98)90085-4

2. Mulu W, Yimer M, Zenebe Y, Abera B. Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot referral Hospital, Ethiopia: a cross sectional study. BMC Women’s Health. (2015) 15:42. doi: 10.1186/s12905-015-0197-y

3. Powell AM, Nyirjesy P. Recurrent vulvovaginitis. Best Pract Res Clin Obstetr Gynaecol. (2014) 28:967–76. doi: 10.1016/j.bpbgymn.2014.07.006

4. Nicolici LM, Kopicko J, Kassie A, Petros H, Clark RA, Kissinger P. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sexually Trans Dis. (2000) 27:284–8. doi: 10.1097/00007435-200005000-00009

5. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygap SE. Mixed vaginitis—more than coinfection and with therapeutic implications. Curr Infect Dis Rep. (2013) 15:104–8. doi: 10.1007/s11908-013-0325-5

6. Kalia N, Singh J, Sharma S, Kamboj SS, Arora H, Kaur M. Prevalence of vulvovaginal in infections and species specific distribution of vulvovaginal candidiasis in married women of north India. Int J Cur Microbiol App Sci. (2015) 4:253–66.

7. Masha SC, Cools P, Sanders EJ, Vaneechoutte M, Crucitti T. Trichomomas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. Sex Transm Infect. (2019) 95:36–42. doi: 10.1136/sextrans-2018-053713

8. van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. Hum Reprod. (2013) 28:1809–15. doi: 10.1093/humrep/det096

9. Toth B, Würfel W, Bohlmann MK, Gillessen-Kaesbach G, Nawroth GB. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by Lactobacillus iners in health and dysbiosis. Microbiome. (2013) 1:12. doi: 10.1186/2049-2618-1-12

10. Vodstrcil LA, Tawn J, Garland SM, Fairley CK, Hocking JS, Law MG, et al. The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS ONE. (2017) 12:e0171856. doi: 10.1371/journal.pone.0171856

11. Ravel J, Gajer P, Abdó Z, Schneider GM, Koenig SS, McCúlle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci. (2011) 108(Suppl. 1):6806–7. doi: 10.1073/pnas.1002611107

12. Macklam JM, Fernandes AD, Dó Bella M, Hammond JA, Reid G, Gloor GB. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by Lactobacillus iners in health and dysbiosis. Microbiome. (2013) 1:12. doi: 10.1186/2049-2618-1-12

13. Petricevic L, Domig KJ, Nierscher FJ, Sandhofer MJ, Fidesser M, Kronedorfer I, et al. Characterisation of the vaginal Lactobacillus microbiota associated with preterm delivery. Sci Rep. (2014) 4:5136. doi: 10.1038/srep05136

14. Falkow S. Molecular Koch’s postulates applied to microbial pathogenicity. Rev Infect Dis. (1988) 1988:S274–6. doi: 10.1093/cid/10.Supplement_2.S274

15. Gonçalves R, Ferreira C, Alves CT, Henriques M, Azieredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. (2016) 42:905–27. doi: 10.3109/1040841X.2015.1091805

16. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraeten H, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS ONE. (2014) 9:e105998. doi: 10.1371/journal.pone.0105998

17. Medzhitov R. Origin and physiological roles of inflammation. Nature. (2008) 454:428. doi: 10.1038/nature07201

18. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. (2005) 206:306–35. doi: 10.1111/j.0903-1926.2005.00287.x

19. Kaushic C, Ferreira VH, Kafka JK, Nazli A. HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment. Am J Reprod Immunol. (2010) 63:566–75. doi: 10.1111/j.1600-0897.2010.00843.x

20. Hickey DK, Patel MV, Fahey J, Wira CR. Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections. J Reprod Immunol. (2011) 88:185–94. doi: 10.1016/j.jri.2011.01.005

21. Moncla BJ, Chappell CA, Debo BM, Meyn LA. The effects of hormones and vaginal microflora on the glycome of the female genital tract: cervical-vaginal fluid. PLoS ONE. (2016) 11:e0158687. doi: 10.1371/journal.pone.0158687

22. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. (2015) 6:81. doi: 10.3389/fphys.2015.00081

23. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV. Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol. (2011) 65:196–211. doi: 10.1111/j.1600-0897.2011.00970.x

24. Kurita T. Developmental origin of vaginal epithelium. Differentiation. (2010) 80:99–105. doi: 10.1016/j.diff.2010.06.007

25. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. (2008) 8:279. doi: 10.1038/nri2125

26. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. (2010) 63:566–75. doi: 10.1016/j.diff.2010.06.007

27. Moncla BJ, Chappell CA, Debo BM, Meyn LA. The effects of hormones and vaginal microflora on the glycome of the female genital tract: cervical-vaginal fluid. PLoS ONE. (2016) 11:e0158687. doi: 10.1371/journal.pone.0158687

28. Fichorova RN, Cronin AO, Lien E, Anderson DJ, Ingalls RR. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. Inflamm Med. (2015) 2015:794143. doi: 10.1155/2015/794143

29. Fazeli A, Bruce C, Anumba DO. Characterization of Toll-like receptors in the female reproductive tract in humans. Hum Reprod. (2005) 20:1372–8. doi: 10.1093/humrep/deh775

AUTHOR CONTRIBUTIONS

NK collected the literature and wrote the manuscript. JS and MK designed and critically checked the manuscript.

ACKNOWLEDGMENTS

The authors express their sincere gratitude to University Grants Commission, New Delhi, Govt. of India for providing Senior Research Fellowship to NK.

Frontiers in Immunology | www.frontiersin.org 15 August 2019 | Volume 10 | Article 2034
30. Hart KM, Murphy AJ, Barrett KT, Wira CR, Guyle PM, Pioli PA. Functional expression of pattern recognition receptors in tissues of the human female reproductive tract. J Reprod Immunol. (2009) 80:33–40. doi: 10.1016/j.jri.2008.12.004

31. Brown GD. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol. (2006) 6:633. doi: 10.1038/nri1745

32. Bulla R, De Seta F, Radillo O, Agostini C, Durigutto P, Pellis V, et al. Mannose-binding lectin is produced by vaginal epithelial cells and its level in the vaginal fluid is increased by progesterone. Mol Immunol. (2010) 48:281–6. doi: 10.1016/j.molimm.2010.07.016

33. Pioli PA, Amiel E, Schaefer TM, Connolly JE, Wira CR, Guyre PM. Mucosal Immunol. (2005) 9:548–56. doi: 10.1210/jc.2004-0241

34. Bulla R, De Seta F, Crovella S, Durigutto P, Pellis V, et al. Evidence for the presence of toll-like receptor 4 system in the human endometrium. J Clin Endocrinol Metabol. (2009) 95:548–56. doi: 10.1210/jc.2009-1126

35. Bechinger B, Gorr SU. Antimicrobial peptides: mechanisms of action and resistance. J Dental Res. (2017) 96:254–60. doi: 10.1177/0022034516679037

36. Bechinger B, Gorr SU. Antimicrobial peptides: mechanisms of action and resistance. J Dental Res. (2017) 96:254–60. doi: 10.1177/0022034516679037

37. Bechinger B, Gorr SU. Antimicrobial peptides: mechanisms of action and resistance. J Dental Res. (2017) 96:254–60. doi: 10.1177/0022034516679037

38. Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol. (2013) 425:4965–80. doi: 10.1016/j.jmb.2013.09.038

39. Kalia N, Singh J, Sharma S, Arora H, Kaur M. Genetic and phenotypic screening of mannose-binding lectin in relation to risk of recurrent vulvovaginal infections in women of North India: a prospective cohort study. Front Microbiol. (2017) 8:75. doi: 10.3389/fmicb.2017.00075

40. Rogers H, Williams DW, Feng GJ, Lewis MA, Wei XQ. Role of bacterial lipopolysaccharide in enhancing host immune response to Candida albicans. Clin Dev Immunol. (2013) 2013:320168. doi: 10.1155/2013/320168

41. Kalia N, Kaur M, Sharma S, Singh J. A comprehensive in silico analysis of toll-like receptor 4 system in the human endometrium. J Reprod Immunol. (2014) 112:1–14. doi: 10.1016/j.jri.2014.08.005

42. Libby EK, Defraite K, Mechech E, Adelson M, Trama JP. Atoxopoeinia vaginas triggers in innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. (2008) 10:439–46. doi: 10.1016/j.micinf.2008.01.004

43. Eade CR, Caz C, Wood MP, Anastos K, Patterson BK, Gupta P, et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS ONE. (2012) 7:e50106. doi: 10.1371/journal.pone.0050106

44. Marconi C, Donders GG, Parada CM, Giraldos PC, da Silva MG. Do Atoxopoeia vaginae, Megasphaera spp. and Leptotrichia sp change the local innate immune response and sialidase activity in bacterial vaginosis? Sex Transm Infect. (2013) 89:167–73. doi: 10.1136/sextrans-2012-050616

45. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelium in a species-specific manner. J Infect Dis. (2014) 209:1989–99. doi: 10.1093/infdis/jiu004

46. Vick EJ, Park HS, Huff KA, Brooks KM, Farone AL, Farone MB. Gardnerella vaginalis enters vaginal mucosa through a non-TLR entry pathway. J Infect Dis. (2013) 200:409–17. doi: 10.1093/infdis/jist047

47. Eade CR, Caz C, Wood MP, Anastos K, Patterson BK, Gupta P, et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS ONE. (2012) 7:e50106. doi: 10.1371/journal.pone.0050106

48. Marconi C, Donders GG, Parada CM, Giraldos PC, da Silva MG. Do Atoxopoeia vaginae, Megasphaera spp. and Leptotrichia sp change the local innate immune response and sialidase activity in bacterial vaginosis? Sex Transm Infect. (2013) 89:167–73. doi: 10.1136/sextrans-2012-050616

49. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelium in a species-specific manner. J Infect Dis. (2014) 209:1989–99. doi: 10.1093/infdis/jiu004

50. Vick EJ, Park HS, Huff KA, Brooks KM, Farone AL, Farone MB. Gardnerella vaginalis enters vaginal mucosa through a non-TLR entry pathway. J Infect Dis. (2013) 200:409–17. doi: 10.1093/infdis/jist047

51. Figueiredo AS, Schumacher A. The T helper type 1/2/regulatory T cell paradigm in pregnancy. Immunology. (2016) 148:13–21. doi: 10.1111/imn.12395

52. Al-Harthi L, Spear GT, Hashemi FB, Landay A, Sha BE, Roebuck KA. A human immunodeficiency virus (HIV)-inducing factor from the female genital tract activates HIV-1 gene expression through the K/B enhancer. J Infect Dis. (1998) 178:1343–51. doi: 10.1086/314444

53. Zariford MR, Novak RM, Laurain N, Sha BE, Graham P, Spear GT. Induction of tumor necrosis factor–α secretion and toll-like receptor 2 and 4 mRNA expression by genital mucosal fluids from women with bacterial vaginosis. J Infect Dis. (2005) 191:1913–21. doi: 10.1086/429922

54. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunol. (2013) 42:965–76. doi: 10.1016/j.immuni.2015.04.019

55. Kalia N, Singh J, Sharma S, Arora H, Kaur M. Genetic and phenotypic screening of mannose-binding lectin in relation to risk of recurrent vulvovaginal infections in women of North India: a prospective cohort study. Front Microbiol. (2017) 8:75. doi: 10.3389/fmicb.2017.00075

56. Rogers H, Williams DW, Feng GJ, Lewis MA, Wei XQ. Role of bacterial lipopolysaccharide in enhancing host immune response to Candida albicans. Clin Dev Immunol. (2013) 2013:320168. doi: 10.1155/2013/320168

57. Kalia N, Kaur M, Sharma S, Singh J. A comprehensive in silico analysis of toll-like receptor 4 system in the human endometrium. J Reprod Immunol. (2014) 112:1–14. doi: 10.1016/j.jri.2014.08.005

58. Libby EK, Defraite K, Mechech E, Adelson M, Trama JP. Atoxopoeinia vaginas triggers in innate immune response in an in vitro model of bacterial vaginosis. Microbes Infect. (2008) 10:439–46. doi: 10.1016/j.micinf.2008.01.004

59. Eade CR, Caz C, Wood MP, Anastos K, Patterson BK, Gupta P, et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS ONE. (2012) 7:e50106. doi: 10.1371/journal.pone.0050106

60. Marconi C, Donders GG, Parada CM, Giraldos PC, da Silva MG. Do Atoxopoeia vaginae, Megasphaera spp. and Leptotrichia sp change the local innate immune response and sialidase activity in bacterial vaginosis? Sex Transm Infect. (2013) 89:167–73. doi: 10.1136/sextrans-2012-050616
Kalia et al. Immunomodulation in RVVI

83. Orfanelli T, Jayaram A, Doulaveris G, Forney LJ, Ledger WJ, Witkin SS. Imbert M, Blondeau R. On the iron requirement of lactobacilli grown in chemically defined medium. *Curr Microbiol.* (2004) 116:152–6. doi: 10.1007/ejogb.2004.02.010

82. Valore EV, Wiley DJ, Ganz T. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. *Infect Dis Obstet Gynecol.* (2005) 13:207–11. doi: 10.1155/2005/338107

81. Balu RB, Savitz DA, Ananth CV, Hartmann KE, Miller WC, Thorp JM, Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, et al. Cervicovaginal levels of proinflammatory cytokines are increased during chlamydial infection in bacterial vaginosis but not in lactobacilli-dominated flora. *J Lower Genital Tract Dis.* (2014) 18:261–5. doi: 10.1097/LGT.0000000000000197

80. Cauci S, Guaschino S, de Aloysio D, Driussi S, De Santo D, Pennacchioni P, Lopez-Castejon G, Brough D. Understanding the mechanism of vaginal fluid: relation to vaginal components and bacterial composition. *Reprod Sci.* (2016) 23:159–67. doi: 10.1177/1933719115601500

79. Platz-Christensen JJ, Mattsby-Baltzer I, Thomsen P, Wiqvist N. Endotoxin-mediated signaling. *Clin Microbiol Rev.* (2017) 30:1357417.e1–e11. doi: 10.1101/652325.2017.1357417

78. Giraldo PC, de Carvalho JBJ, do Amaral RLG, da Silveira Gonçalves AK, Eleutério J, Guimarães F. Identification of immune cells by flow cytometry in vaginal lavages from women with vulvovaginitis and normal microflora. *Am J Reprod Immunol.* (2016) 67:198–205. doi: 10.1111/1600-0897.2011.01093.x

77. Lopez-Castejon G, Brough D. The human cathelicidin LL-37—A pore-forming antibacterial peptide induced in cervicovaginal epithelial cells by gardnerella vaginalis: the “invisible man” of bacterial vaginosis? *PLoS ONE.* (2011) 6:e26580.e1–e9. doi: 10.1371/journal.pone.0026580

76. Gabrielli E, Sabattini S, Rossetelli S, Eberle KE, Peters BM, Vogl T, McKenzie AN, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. *Nature.* (2016) 532:64. doi: 10.1038/nature17625

75. Moyes DL, Wilson D, Richardson JP, Mogavero S, Tang SL, Werneck E, et al. Candidalysin drives epithelial signaling, neutrophil recruitment, and immunopathology at the vaginal mucosa. *Infect Immun.* (2017) 85:100645. doi: 10.1128/IAI.00645-17

74. Moyes DL, Runglall M, Murciano C, Shen C, Nayar D, Thavaraj S, et al. Candida albicans yeast and hyphae are discriminated by MAPK signaling in vaginal epithelial cells. *PLoS ONE.* (2011) 6:e26580.e1–e9. doi: 10.1371/journal.pone.0026580

73. Richardson JP, Willems HM, Moyes DL, Shoie B, Barker KS, Tan SL, et al. Candidalysin drives epithelial signaling, neutrophil recruitment, and immunopathology at the vaginal mucosa. *Infect Immun.* (2017) 85:100645. doi: 10.1128/IAI.00645-17

72. Bertran T, Brachet P, Varelle-Delarbre M, Falenta J, Dosgillib A, Vasson MP, et al. Slight pro-inflammatory immunomodulation properties of dendritic cells by gardnerella vaginalis the “invisible man” of bacterial vaginosis? *J Immunol Res.* (2016) 2016:9747480. doi: 10.1155/2016/9747480

71. Genc MR, Vardhana S, Delaney ML, Onderdonk A, Tuomala R, Wilson D, et al. Vaginal lactobacilli in adolescents: presence and relationship to high risk of HIV infection. *BMC Microbiol.* (2008) 8:229. doi: 10.1186/1471-2180-8-229

70. Alvarez-Olmos MI, Barousse MM, Rajan L, Van Der Pol BJ, Fortenberry D, Orr D, et al. Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to bacterial vaginosis. *Sexually Trans Dis.* (2004) 31:393–400. doi: 10.1097/01.OLQ.0000130454.83883.E9

69. Caucci S, Guaschino S, de Aloysio D, Driussi S, De Santo D, Penacchioni P, et al. Interrelationships of interleukin-8 with interleukin-1β and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. *Mol Hum Reprod.* (2003) 9:953–8. doi: 10.1093/molehr/gag003

68. Frew L, Makieva S, McKinlay AT, McHugh BJ, Doust A, Norman JE, et al. Human cathelicidin production by the cervix. *PLoS ONE.* (2014) 9:e103434. doi: 10.1371/journal.pone.0103434

67. Xiándí D, Pacor S, Benincasa M, Scochi M, Gennaro R, Tossi A. The human cathelicidin LL-37—A pore-forming antibacterial peptide and host-cell modulation. *Biophys Acta.* (2016) 1858:54–66. doi: 10.1016/j.bbapap.2015.11.003

66. Nijink A, Hancock RE. The roles of cathelicidin LL-37 in immune defenses and novel clinical applications. *Curr Opin Hematol.* (2009) 16:41–7. doi: 10.1097/MOH.0b013e328383a157

65. Pino A, Giunta G, Randazzo CL, Caruso S, Caggia C, Cianci A. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. *Microb Ecol Health Dis.* (2017) 28:1537417.e1–e11. doi: 10.1080/16512235.2017.1537417

64. Giraldo PC, de Carvalho JBJ, do Amaral RLG, da Silveira Gonzalves AK, Eleutério J, Guimarães F. Identification of immune cells by flow cytometry in vaginal lavages from women with vulvovaginitis and normal microflora. *Am J Reprod Immunol.* (2016) 67:198–205. doi: 10.1111/1600-0897.2011.01093.x

63. John EPS, Martinson J, Simoes JA, Landay AL, Spear GT. Dendritic cell activation and maturation induced by mucosal fluid from women with bacterial vaginosis. *Clin Immunol.* (2007) 125:95–102. doi: 10.1016/j.clim.2007.06.004

62. Bertran T, Brachet P, Varelle-Delarbre M, Falenta J, Dosgilib A, Vasson MP, et al. Slight pro-inflammatory immunomodulation properties of dendritic cells by gardnerella vaginalis the “invisible man” of bacterial vaginosis? *J Immunol Res.* (2016) 2016:9747480. doi: 10.1155/2016/9747480

61. Bertran T, Brachet P, Varelle-Delarbre M, Falenta J, Dosgilib A, Vasson MP, et al. Slight pro-inflammatory immunomodulation properties of dendritic cells by gardnerella vaginalis the “invisible man” of bacterial vaginosis? *J Immunol Res.* (2016) 2016:9747480. doi: 10.1155/2016/9747480

60. Bertran T, Brachet P, Varelle-Delarbre M, Falenta J, Dosgilib A, Vasson MP, et al. Slight pro-inflammatory immunomodulation properties of dendritic cells by gardnerella vaginalis the “invisible man” of bacterial vaginosis? *J Immunol Res.* (2016) 2016:9747480. doi: 10.1155/2016/9747480

59. Cauci S, Guaschino S, de Aloysio D, Driussi S, De Santo D, Pennacchioni P, Lopez-Castejon G, Brough D. Understanding the mechanism of vaginal fluid: relation to vaginal components and bacterial composition. *Reprod Sci.* (2016) 23:159–67. doi: 10.1177/1933719115601500
103. Dühring S, Germerodt S, Skerka C, Zipfel PF, Dandekar T, Schuster S. Host-pathogen interactions between the human innate immune system and Candida albicans—understanding and modeling defense and evasion strategies. *Front Microbiol.* (2015) 6:625. doi: 10.3389/fmicb.2015.00625

104. Ip WK, Lau YL. Role of mannose-binding lectin in the innate defense against *Candida albicans* enhancement of complement activation, but lack of opsonic function, in phagocytosis by human dendritic cells. *J Infect Dis.* (2004) 190:632–40. doi: 10.1086/422397

105. Henic E, Thiel S, Mähr PA. Mannan-binding lectin in women with a history of recurrent vulvovaginal candidiasis. *Eur J Obstetrics Gynecol Reprod Biol.* (2010) 148:163–5. doi: 10.1016/j.ejogrb.2009.10.008

106. Ghazanfari M, Falahati M, Fattahi A, Bazrafshan F, Nami S, Hosseinzadeh M, et al. Is MBL serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? *Myocos.* (2017) 2017:12723. doi: 10.1111/mic.12723

107. Liu F, Liao Q, Liu Z. Mannose-binding lectin and vulvovaginal candidiasis. *Clin Infect Dis.* (2003) 37:733–7. doi: 10.1086/377234

108. Babula O, Lazdane G, Kroica J, Ledger WJ, Witkin SS. Relation between recurrent vulvovaginal candidiasis, vaginal concentrations of mannose-binding lectin, and a mannose-binding lectin gene polymorphism in Latvian women. *Clin Infect Dis.* (2003) 37:733–7. doi: 10.1086/377234

109. Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown et al. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. *Cell Microbiol.* (2006) 8:686–76. doi: 10.1111/j.1462-5822.2006.00659.x

110. Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown et al. Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. *Cell Microbiol.* (2006) 8:686–76. doi: 10.1111/j.1462-5822.2006.00659.x

111. Kenny EF, Herzig A, Krüger R, Muth A, Mondal S, Thompson PR, et al. Autophagy and reactive oxygen species are involved in neutrophil extracellular traps released by *C. albicans* morphotypes. *Front Microbiol.* (2016) 7:879. doi: 10.3389/fmicb.2016.00879

112. Kenny EF, Herzig A, Krüger R, Muth A, Mondal S, Thompson PR, et al. Diverse stimuli engage different neutrophil extracellular trap pathways. *Elife.* (2017) 6:e24437. doi: 10.7554/eLife.24437

113. Byrd AS, O’Brien XM, Johnson CM, Lavigne LM, Reicherter JS. An extracellular matrix–based mechanism of rapid neutrophil extracellular trap formation in response to *Candida albicans*. *J Immunol.* (2013) 190:4136–48. doi: 10.4049/jimmunol.1202871

114. Nani S, Fumagalli L, Sinha U, Kamen L, Scapini P, Berton G. Src family kinases and Syk are required for neutrophil extracellular trap formation in response to β-glucan particles. *J Innate Immun.* (2015) 7:59–73. doi: 10.1159/000365249

115. Fidel PL, Barousse M, Espinoza T, Ficarra M, Sturtevant J, Martin DH, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. *Infect Immun.* (2004) 72:2393–46. doi: 10.1128/IAI.72.5.2393-2946.2004

116. Black CA, Eyles FM, Russell A, Dunkley ML, Clancy RL, Bealey KW. Acute neutropenia decreases inflammation associated with murine vaginal candidiasis but has no effect on the course of infection. *Infect Immun.* (1998) 66:1273–5.

117. Peters BM, Palmer GE, Nash AK, Lilly EA, Fidel PL, Noverr MC. Fungal morphogenetic pathways are required for the hallmark inflammatory response during *Candida albicans* vaginitis. *Infect Immun.* (2014) 82:532–43. doi: 10.1128/IAI.01417-13

118. Nanto J, Peters BM, Noverr MC, Fidel PL. Novel mechanism behind the immunopathogenesis of vulvovaginal candidiasis: “neutrophil anergy”. *Infect Immun.* (2018) 86:00684–17. doi: 10.1128/IAI.00684-17

119. Miramon P, Kasper L, Hube B. Thriving within the host: *Candida* spp. interactions with phagocytic cells. *Med Microbiol Immunol.* (2013) 202:183–95. doi: 10.1007/s00430-013-0288-z

120. Cheng SC, Joostena LA, Kulberg BJ, Neta MG. Interplay between *Candida albicans* and the mammalian innate host defense. *Infect Immun.* (2012) 80:1304–13. doi: 10.1128/IAI.00646-11

121. van de Veerdonk FL, Joostena LA, Shaw PJ, Smeekens SP, Malireddi RK, et al. The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. *Eur J Immunol.* (2011) 41:2260–8. doi: 10.1002/eji.201041226

122. Talaei Z, Sheikhbahaei S, Ostadi V, Hakemi MG, Meidani M, Nahshineh E, et al. The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal *Candida albicans* infections. *Infect Immun.* (2014) 82:1173–80. doi: 10.1128/IAI.01335-13

123. Conti HR, Ghilardi N, et al. The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal *Candida albicans* infections. *Infect Immun.* (2006) 74:5513–8. doi: 10.4049/jimmunol.74.9.5513

124. Heinsbroek SE, Taylor PR, Rosas M, Willment JA, Williams DI, Gordon S, et al. Expression of functionally different dectin-1 isoforms by murine macrophages. *J Immunol.* (2006) 176:5513–8. doi: 10.4049/jimmunol.176.9.5513

125. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. *N Engl J Med.* (2009) 361:1760–70. doi: 10.1056/NEJMoa0901053

126. Li D, Dong B, Tong Z, Wang Q, Liu W, Yang Y, et al. MBL-mediated opsonophagocytosis of *Candida albicans* by human neutrophils is coupled with intracellular Dectin-1-triggered ROS production. *PLoS ONE.* (2014) 7:e50589. doi: 10.1371/journal.pone.0050589

127. LeBlanc DM, Barousse MM, Fidel PL. Role for dendritic cells in immunoregulation during experimental vaginal candidiasis. *Infect Immun.* (2006) 74:3213–21. doi: 10.1128/IAI.01824-05

128. De Bernardis F, Lucciariini R, Boccarnea M, Amantini C, Arancia S, Morrone S, et al. Phenotypic and functional characterization of vaginal dendritic cells in a rat model of *Candida albicans* vaginitis. *Infect Immun.* (2006) 74:4282–94. doi: 10.1128/IAI.01714-05

129. Nawrot U, Grzybek-Hryncewicz K, Zielska U, Czarny A, Podwinski J. The role of MBL in the development of recurrent vulvovaginal candidiasis. *Front Microbiol.* (2015) 2017:12723. doi: 10.3389/fmicb.2016.00879

130. Fidel PL Jr, Lynch ME, Lopez VR, Sobel JD, Robinson S. Systemic cell-mediated immune reaction in women with recurrent vulvovaginal
women in Central Vietnam. J Infect Dev Countries. (2015) 9:655–60. doi: 10.3855/jidc.7190

178. Provenzano D, Alderete JF. Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis. Infect Immun. (1993) 61:3388–95.

179. Yadav M, Dubey ML, Gupta I, Malla N. Cysteine proteinase 30 (CP30) and antibody response to CP30 in serum and vaginal washes of symptomatic and asymptomatic Trichomonas vaginalis-infected women. Parasite Immunol. (2007) 29:359–65. doi: 10.1111/j.1365-3024.2007.00952.x

180. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antiinflammatory defense. World Allergy Organ J. (2012) 5:9. doi: 10.1097/WOX.0b013e3182439613

181. Lugrin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. The role of oxidative stress during inflammatory processes. Biol Chem. (2014) 395:203–30. doi: 10.1515/hac-2013-0241

182. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. (2007) 87:315–424. doi: 10.1152/physrev.00029.2006

183. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neutrophil activation in vivo. Antioxid Redox Signal. (2011) 15:986–95. doi: 10.1089/ars.2010.3666

184. Provenzano D, Alderete JF. Analysis of human immunoglobulin-degrading cysteine proteinases of Trichomonas vaginalis. Infect Immun. (1993) 61:3388–95.

185. Kalia et al. Immunomodulation in RVVI

186. Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, Skerka C. The yeast Candida albicans evades human complement attack by

187. Simhan HN, Anderson BL, Krohn MA, Heine RP, de Tejada BM, Landers DV, et al. Host immune consequences of asymptomatic Trichomonas vaginalis infection in pregnancy. Am J Obstet Gynecol. (2007) 196:59–e1. doi: 10.1016/j.ajog.2006.08.035

188. Escario A, Barriot AG, Duarte JS, Escario JA. Immunohistochemical study of the vaginal inflammatory response in experimental trichomoniasis. Acta Tropica. (2011) 114:22–30. doi: 10.1016/j.actatropica.2009.12.002

189. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. (2010) 10:210. doi: 10.1038/nri2725

190. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. (2012) 36:401–14. doi: 10.1016/j.immuni.2012.01.009

191. Li H, Horke S, Förstermann U. Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol Sci. (2013) 34:313–9. doi: 10.1016/j.tips.2013.03.007

192. Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical signaling. J Exp Med. (2006) 203:2377–89. doi: 10.1084/jem.20060845

193. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. (2006) 72:1493–505. doi: 10.1016/j.bcp.2006.04.011

194. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. (2010) 10:210. doi: 10.1038/nri2725
vesicles modify the cytokine profile and reduce inflammation in parasite-infected mice. *Parasite Immunol.* (2017) 39:e12426. doi: 10.1111/pim.12426

256. Alderete JF, Demas P, Gombosova A, Valent MICHAL, Yanoska A, Fabusova H, et al. Phenotypes and protein-epitope phenotypic variation among fresh isolates of *Trichomonas vaginalis*. *Infect Immunity.* (1987) 55:1037–41.

257. Alderete JF. Iron modulates phenotypic variation and phosphorylation of P270 in double-stranded RNA virus-infected *Trichomonas vaginalis*. *Infect Immunity.* (1999) 67:4298–302.

258. Genc MR, Onderdonk AB, Vardhana S, Delaney ML, Norwitz ER, Kalia et al. Immunomodulation in RVVI

259. Goepfert AR, Varner M, Ward K, Macpherson C, Klebanoff M, Goldenberg RL et al. Differences in inflammatory cytokine and Toll-like receptor genes and bacterial vaginosis in pregnancy. *Am J Obstet Gynecol.* (2005) 193:1478–85. doi: 10.1016/j.ajog.2005.03.053.

260. Gómez LM, Sammel MD, Appleby DH, Elovitz MA, Baldwin DA, Jeffcoat MK, et al. Evidence of a gene-environment interaction that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and DNA variants in genes that control the inflammatory response. *Am J Obstet Gynecol.* (2010) 202:386–e1. doi: 10.1016/j.ajog.2010.01.042.

261. Macones GA, Parry S, Elkousy M, Clothier B, Ural SH, Strauss JF. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. *Am J Obstet Gynecol.* (2004) 190:1504–8. doi: 10.1016/j.ajog.2004.01.001.

262. Genç MR, Vardhana S, Delaney ML, Witkin SS, Onderdonk AB. TNF-α polymorphism in the promoter region of TNF and bacterial vaginosis: a role for asymptomatic bacterial vaginosis and interleukin-1 receptor antagonist gene polymorphisms and recurrent vulvovaginal candidiasis. *Arq Gynecol Obstetr.* (2012) 285:149–53. doi: 10.1007/s00404-011-1920-z.

263. Giraldo PC, Babula O, Gonçalves AKS, Linhares IM, Amaral RL, Ledger WJ, et al. Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. *Obstet Gynecol.* (2007) 109:1123–8. doi: 10.1097/AOG.0b0000d0368.17555.a5.

264. Kalia N, Singh J, Sharma S, Kaur M. SNPs in 3′-UTR region of MBL2 increases susceptibility to recurrent vulvovaginal infections by altering sMBL levels. *Immunobiology.* (2019) 224:42–9. doi: 10.1007/j.6imbio.2018.10.009.

265. Kalia N, Singh J, Sharma S, Kaur M. Impact of SNPs interplay across the locus of MBL2, between MBL and Dectin-1 gene, on women’s risk of developing recurrent vulvovaginal infections. *Cell Biosci.* (2019) 9:35. doi: 10.1186/s13578-019-0300-4.

266. Glocker EO, Hemnigs A, Nabavi M, Schäffer AA, Woelcner C, Salzer U, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. *N Engl J Med.* (2009) 361:1727–35. doi: 10.1056/NEJMoA0810719.

267. Drummond RA, Brown GD. Signalling C-type lectins in antimicrobial immunity. *PLoS Pathog.* (2013) 9:e1003417.e1–e3. doi: 10.1371/journal.ppat.1003417.

268. Heyl KA, Klassert TE, Heinrich A, Müller MM, Kläe E, Diennemann H, et al. Dectin-1 is expressed in human lung and mediates the proinflammatory immune response to nontypeable Haemophilus influenzae. *mBio.* (2014) 5:e01492-14.e1-e9. doi: 10.1128/mBio.01492-14.

269. Valdimarsson H. Infusion of plasma-derived mannann-binding lectin (MBL) into MBL-deficient humans. *Biochem Soc Trans.* (2003) 31:768–9. doi: 10.1042/bst0310768.

270. Valdimarsson H, Vikingsdottir T, Bang P, Sævarsdottir S, Gudjonsson JE, Oskarsson O, et al. Human plasma-derived mannan-binding lectin: a phase I safety and pharmacokinetic study. *Scand J Immunol.* (2004) 59:97–102. doi: 10.1111/j.0300-9475.2004.01357.x.

271. Bang P, Laursen I, Thornberg K, Schierbeck J, Nielsen B, Valdimarsson H, et al. The pharmacokinetic profile of plasma-derived mannann-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicemia. *Scand J Infect Dis.* (2008) 40:44–8. doi: 10.1080/00365540701522959.

272. Summerfield JA. Clinical potential of mannann-binding lectin-replacement therapy. *Biochem Soc Trans.* (2003) 30:770–3. doi: 10.1042/bst030770.

273. Yee C. Adoptive T cell therapy: points to consider. *Curr Opin Immunol.* (2018) 51:197–203. doi: 10.1016/j.coi.2018.04.007.

274. Pelfrene E, Mura M, Sanches AC, Cavaleri M. Monoclonal antibodies as anti-infective products: a promising future? *Clin Microbiol Infect.* (2018) 24:1024. doi: 10.1016/j.cmi.2018.04.024.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Kalia, Singh and Kaur. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.